CellaVision AB: Interim report January - June 2013
(Thomson Reuters ONE) -
Weak quarter but continued global market initiatives and sales successes in Asia
January 1 - June 30, 2013
* Net sales were SEK 69.9 million (83.8).
* Operating profit was SEK -1.0 million (9.9).
* Profit before tax was SEK -2.0 million (9.4).
* Earnings per share were SEK -0.08 (0.24).
* Cash and cash equivalents were SEK 41.1 million (47.5) at the end of the
period.
April 1 - June 30 2013
* Net sales were SEK 36.1 million (43.4).
* Operating profit was SEK -0.4 million (4.5).
* Profit before tax was SEK -0.5 million (5.0).
* Earnings per share were SEK -0.01 (0.13).
Significant events during the second quarter
* CellaVision and Sysmex published the news of a jointly developed product,
the DI-60. CellaVision's digital image analysis technology has been
integrated with Sysmex cell counter and sample preparation instrument. The
first sales were made in Q1 and Q2.
* Another sales channel in Europe: CellaVision and Beckman Coulter increased
their cooperation by adding EMEA to their global distribution agreement.
* The first sale of CellaVision's new product CellaVision® Proficiency
Software was made to the Swedish quality assessment organization Equalis.
* Magnus Blixt took up his position as new CFO and Göran Granqvist was
appointed VP Quality.
Key Ratios
(SEK million) Apr-Jun Apr-Jun Jan-Jun Jan-Jun Full year
2013 2012 2013 2012 2012
Net sales 36.1 43.4 69.9 83.8 169.5
Gross profit 23.4 28.7 45.4 55.8 110.1
Operating profit -0.4 4.5 -1.0 9.9 20.7
Operating margin, % Neg. 10.5 Neg. 11.8 12.2
Profit/loss before tax -0.5 5.0 -2.0 9.4 18.6
Cash flow for the -11.4 -9.0 -5.1 -9.3 -10.6
period
Comments by CellaVision's CEO Yvonne Mårtensson:
"Our sales successes in China and Japan continued in the second quarter but in
North America and Europe many hospitals are still holding off, and several deals
have been delayed. Considering the current conditions in our main markets it is
gratifying that sales in Asia and the Pacific region, which is our long-term
growth market, continue to show an upward trend.
Activity in the market has been high during the year, with several important
business achievements as a consequence. We continue to focus efforts on
visibility through strong partners and an increased product portfolio to build
the company and be prepared when the market turns. The four largest players in
the market now have an agreement with us, which emphasizes the global uniqueness
of our product offering. Training is in progress of our three new partners and
all have now submitted their first order. As regards the new integrated DI-60
product, we will deliver the first major order to Sysmex in Europe already at
the end of July.
In the coming six months we will see a slow improvement and estimate that for
the full year, we will report profitability, though without any total growth.
The market is difficult to read, but in the longer term conditions for high
growth are good. The health care sector's streamlining and quality assurance
needs continue to grow."
Questions concerning the report can be addressed to:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82. Email: yvonne.martensson(at)cellavision.se
Magnus Blixt, CFO, CellaVision AB
Tel: +46 708 33 81 68. Email: magnus.blixt(at)cellavision.se
CellaVision AB Interim report January ? June 2013:
http://hugin.info/132164/R/1716446/570746.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1716446]
Unternehmensinformation / Kurzprofil:
Datum: 17.07.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 279098
Anzahl Zeichen: 4777
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB: Interim report January - June 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
